Development and Verification of Diagnosis Model for Papillary Thyroid Cancer Based on Pyroptosis-Related Genes: A Bioinformatic and in vitro Investigation
Lingling Ding,Guowan Zheng,Aoni Zhou,Fahuan Song,Lei Zhu,Yefeng Cai,Yehao Guo,Tebo Hua,Yunye Liu,Wenli Ma,Yiqun Hu,Yawen Guo,Chuanming Zheng
DOI: https://doi.org/10.2147/jir.s478989
IF: 4.5
2024-10-29
Journal of Inflammation Research
Abstract:Lingling Ding, 1, &ast Guowan Zheng, 1– 3, &ast Aoni Zhou, 4 Fahuan Song, 1– 3 Lei Zhu, 5 Yefeng Cai, 6 Yehao Guo, 1 Tebo Hua, 7 Yunye Liu, 1 Wenli Ma, 1 Yiqun Hu, 1– 3 Yawen Guo, 1– 3 Chuanming Zheng 1– 3 1 Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310000, People's Republic of China; 2 Zhejiang Provincial Clinical Research Center for Malignant Tumor, Hangzhou, Zhejiang, 310000, People's Republic of China; 3 Zhejiang Key Laboratory of Precision Medicine Research on Head & Neck Cancer, Hangzhou, Zhejiang, 310000, People's Republic of China; 4 Hangzhou Normal University, Hangzhou, Zhejiang, 311121, People's Republic of China; 5 Department of Thyroid Surgery, The Fifth Hospital Affiliated to Wenzhou Medical University, Lishui Central Hospital, Lishui, Zhejiang, 323000, People's Republic of China; 6 Department of Thyroid Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People's Republic of China; 7 Department of Thyroid Surgery, Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang, 315000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yawen Guo; Chuanming Zheng, Department of Head and Neck Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, No. 158, Shangtang Road, Hangzhou, Zhejiang, People's Republic of China, Email ; Background: The incidence of papillary thyroid cancer (PTC) has been increasing annually; however, early diagnosis can improve patient outcomes. Pyroptosis is a programmed cell death modality that has received considerable attention recently. However, no studies have reported using pyroptosis-related genes in PTC diagnosis. Methods: Analyzed 33 pyroptosis-related genes in PTC transcriptome data from the Gene Expression Omnibus database. Subsequently, used the Least Absolute Shrinkage and Selection Operator (LASSO) model to construct a PTC molecular diagnostic model. Furthermore, confirmed differences in the expression of five genes between PTC and non-tumor tissues using immunohistochemistry. Collected 338 PTC and control samples to construct a five-gene PTC diagnostic model, which was then validated using a training set and underwent correlation analysis with immune cell infiltration. Additionally, validated the biological functions of the core gene NOD1 in vitro. Results: The five-gene PTC diagnostic model demonstrated good diagnostic value for PTC. Moreover, identified three reliable subtypes of pyroptosis and found that NOD1 is involved in tumor-suppressive microenvironment formation. Notably, patients with high NOD1 expression had lower Progression-Free Survival (PFS). Additionally, NOD1 expression was positively correlated with immune markers such as CD47, CD68, CD3, and CD8. Lastly, inhibiting NOD1 showed significant anti-PTC activity in vitro. Conclusion: Our results suggest that pyroptosis-related genes can be used for PTC diagnosis, and NOD1 could be a promising therapeutic target. Keywords: pyroptosis-related genes, papillary thyroid cancer, PTC, immune cell infiltration, bioinformatic, diagnosis model Recently, thyroid cancer incidence has increased dramatically worldwide, ranking in the top 10 of all cancer types, seventh in the incidence of malignancies in women, 1 and fourth in Chinese women. 2 In the United States, approximately 43,800 new cases of thyroid cancer are estimated to be diagnosed in 2022. 1 Thyroid cancer is classified into four major tissue types: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), medullary thyroid carcinoma, and anaplastic thyroid carcinoma. PTC and FTC are called differentiated thyroid cancer (DTC). DTC accounts for more than 95% of all cases. 3 Thyroid cancer has a low overall mortality rate. DTC has a good prognosis, 4 with a 10-year survival rate of more than 90–95% 5 due to increasingly advanced screening methods, improved surgical procedures, and corresponding postoperative management and treatment. 6 With the widespread development of fine needle aspiration cytology and the use of the Bethesda reporting system for cytopathology, most thyroid disorders can be diagnosed simply and safely. However, some atypical morphologic changes are difficult to distinguish and require using molecular markers, such as BRAF/RET/ -Abstract Truncated-
immunology